We all have a unique face, fingerprint, voice and signature, so why wouldn’t we have a unique response to the medicine and treatments we receive?

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The European Journal of Medicinal Chemistry.

Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx's development programs for differentiated immunology therapeutics.

The American Society for Radiation Oncology (ASTRO) issued today an updated clinical guideline for physicians who use radiation therapy to treat patients with locally advanced rectal cancer.

The International Association for the Study of Lung Cancer (IASLC) and The Lung Cancer Research Foundation (LCRF) announce the first grant recipient of the IASLC LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award.